Get all your news in one place.
100’s of premium titles.
One app.
Start reading
Investors Business Daily
Investors Business Daily
Technology
INVESTOR'S BUSINESS DAILY and JULIE MAK

Agios Pharmaceuticals Stock Earns IBD Stock Upgrade Again, Hitting 90-Plus RS Rating

Agios Pharmaceuticals stock had its Relative Strength (RS) Rating upgraded from 84 to 91 Monday.

When looking for the best stocks to buy and watch, keep a close on eye on relative price strength. IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price performance over the last 52 weeks stacks up against all the other stocks in our database.

Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.

Looking For Winning Stocks? Try This Simple Routine

Is Agios Pharmaceuticals Stock A Buy?

Agios Pharmaceuticals stock has been rallying this year, up 47% so far this year as of Monday. Now is not an ideal time to jump in since it isn't near a proper buy zone, but see if the stock manages to establish and enter a buy zone in heavy volume.

The biotech company posted 0% earnings growth in its most recent report, while sales growth came in at 65%.

Agios Pharmaceuticals stock earns the No. 70 rank among its peers in the Medical-Biomed/Biotech industry group. Amphastar Pharm, Neurocrine Biosciences and Alkermes are among the top 5 highly rated stocks within the group.

Sign up to read this article
Read news from 100’s of titles, curated specifically for you.
Already a member? Sign in here
Related Stories
Top stories on inkl right now
One subscription that gives you access to news from hundreds of sites
Already a member? Sign in here
Our Picks
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.